Market Cap | 221.52M | P/E | - | EPS this Y | 46.70% | Ern Qtrly Grth | 157,566.70% |
Income | 12.46M | Forward P/E | 27.44 | EPS next Y | 45.50% | 50D Avg Chg | -4.00% |
Sales | 149.54M | PEG | 4.21 | EPS past 5Y | -21.39% | 200D Avg Chg | 6.00% |
Dividend | N/A | Price/Book | 1.26 | EPS next 5Y | 6.00% | 52W High Chg | -14.00% |
Recommedations | 2.00 | Quick Ratio | 1.98 | Shares Outstanding | 57.48M | 52W Low Chg | 33.00% |
Insider Own | 7.32% | ROA | 2.62% | Shares Float | 8.96M | Beta | - |
Inst Own | 49.39% | ROE | 5.91% | Shares Shorted/Prior | 36.85K/45.04K | Price | 4.94 |
Gross Margin | 40.39% | Profit Margin | 8.33% | Avg. Volume | 38,083 | Target Price | 12.00 |
Oper. Margin | 10.70% | Earnings Date | May 8 | Volume | 11,175 | Change | -2.37% |
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
HC Wainwright & Co. | Buy | May 9, 24 |
HC Wainwright & Co. | Buy | Mar 7, 24 |
HC Wainwright & Co. | Buy | Nov 14, 23 |
HC Wainwright & Co. | Buy | Aug 17, 23 |
HC Wainwright & Co. | Buy | May 25, 23 |
HC Wainwright & Co. | Buy | Mar 16, 23 |
Chardan Capital | Buy | Feb 2, 18 |
Jefferies | Buy | Nov 13, 15 |
Jefferies | Buy | Jun 25, 13 |